SECONDARY PREVENTION IN PATIENTS AT EXTREME CARDIOVASCULAR RISK: WHAT CAN WE DO MORE?
Anno:
2025
Prevalence of Heterozygous Familial Hypercholesterolemia (FH) is estimated to be around 1/200-250, which corresponds to 14-34 million cases worldwide. A 27 years-old man was referred to our clinic because of exercise angina. He had a total cholesterol (TC) of 379 mg/dl, HDL 38 mg/dl, LDL 330 mg/dl and TG…